BIOX vs ICL
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 14, 2026
BIOX
ICL
Investment Advisor Scores
ICL
AI Analyst Insights
Detailed Metrics Comparison
| Metric | BIOX | ICL | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 14.9925 | 55.5556 | BIOX |
| PEG Ratio | 1.9521 | 9.44 | BIOX |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -23.4% | 3.1% | ICL |
| Earnings Growth | 34.4% | 1.0% | BIOX |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 60.3/100 | 54.6/100 | BIOX |
| Profit Margin | -108.5% | 4.0% | ICL |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | BUY | ICL |
Relative Price Performance (Last 90 Days)
Current Technical Phase
BIOX
MarkdownPrice below a falling SMA50 (slope -19.1%), weak momentum, RSI 39
ICL
MarkdownPrice below a falling SMA50 (slope -6.7%), weak momentum, RSI 37
Fundamentals Snapshot
| Metric | BIOX | ICL |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 4.2 | 10.2 |
| Trailing P/E | — | 18.0 |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.2% | 0.0% |
| Gross Margin | 0.3% | 0.3% |
| Operating Margin | 0.0% | 0.1% |
| EPS | -1.20 | 0.25 |
| Dividend Yield | — | 0.04% |